Ameriprise
QNRX

Ameriprise’s Quoin Pharmaceuticals QNRX Stock Holding History

Ameriprise’s Portfolio QNRX Stock Details QNRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4
Closed -$256K – 4017
2022
Q2 		$256K Hold
4
– – ﹤0.01% 3622
2022
Q1 		$256K Buy
+4
New +$29.9K ﹤0.01% 3694

Other funds holding QNRX

GSC
Ground Swell Capital Folly Beach, South Carolina $50.7M AUM 30.19% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Ameriprise's QNRX Position: Q3 2022 in Review

Ameriprise sold out of Quoin Pharmaceuticals (QNRX) in Q3 2022, closing a stake of 4 shares — an estimated $256K sold.

Ameriprise first reported a position in QNRX in Q1 2022 and held it in 2 quarters. The position peaked at $256K in Q2 2022. 6 funds tracked by Wall St. Rank hold QNRX as of Q3 2022.

  • Ameriprise reported no remaining Quoin Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Ameriprise sold 4 Quoin Pharmaceuticals shares in Q3 2022, an estimated $256K.
  • Ameriprise first reported a position in Quoin Pharmaceuticals in Q1 2022 and held it in 2 quarters.
  • Ameriprise's Quoin Pharmaceuticals position peaked at $256K in Q2 2022.
  • 6 funds tracked by Wall St. Rank held Quoin Pharmaceuticals as of Q3 2022.

Based on Ameriprise's 13F filing for Q3 2022, filed 14 Nov 2022.